Vanessa DeBruin

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial

Raymond R. Townsend, Felix Mahfoud, David E. Kandzari et al. · The Lancet · 2017 · 734 citations

Medicine, Cardiology, Nephrology +10

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Michael Böhm, Kazuomi Kario, David E. Kandzari et al. · The Lancet · 2020 · 587 citations

Medicine, Cardiology, Nephrology +8

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

Deepak L. Bhatt, Muthiah Vaduganathan, David E. Kandzari et al. · The Lancet · 2022 · 176 citations

Medicine, Cardiology, Nephrology +13

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

David E. Kandzari, Raymond R. Townsend, Kazuomi Kario et al. · Journal of the American College of Cardiology · 2023 · 116 citations

Pharmacy, Nephrology, Pharmacotherapy +17

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design

Michael Böhm, Raymond R. Townsend, Kazuomi Kario et al. · Clinical Research in Cardiology · 2020 · 40 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +16